Celgene's Revlimid improves survival in blood cancer patients

Home › Celgene's Revlimid improves survival in blood cancer patients

Celgene Corp said a late-stage trial of its cancer drug Revlimid met the main goal of improving survival in blood cancer patients.

05.07	Tropical Storm Beryl Graphics
05.07	Atlantic Tropical Weather Outlook
05.07	Tropical Storm Beryl Public Advisory Number 28A
05.07	Summary for Tropical Storm Beryl (AT2/AL022024)
05.07	Still no sign of herd rebuilding
05.07	Eastern North Pacific Tropical Weather Outlook
05.07	Tubi and Pluto lead U.S. surge in free streaming
05.07	Tubi free streaming service launches in the UK
More »

je.st